PPARγ ligands as modulators of inflammatory and catabolic responses in arthritis. An overview

Journal of Rheumatology

Volumn 29, Issue 1, 2002, Pages 3-14

  Fahmi, H ^a   Pelletier, J P ^a   Martel Pelletier, J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE; AD 5075; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CIGLITAZONE; CIPROFIBRATE; CLOFIBRATE; CYCLOOXYGENASE 2; ENGLITAZONE; FATTY ACID; FENOPROFEN; GEMFIBROZIL; IBUPROFEN; ICOSANOID; INDOMETACIN; LIGAND; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; AUTACOID; CELL RECEPTOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ARTHRITIS; ARTICULAR CARTILAGE; ATHEROSCLEROSIS; BONE DESTRUCTION; CATABOLISM; CELL INFILTRATION; DRUG EFFECT; DRUG RECEPTOR BINDING; EDITORIAL; ENTERITIS; GENE ACTIVATION; HUMAN; INFLAMMATION; MODULATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SYNOVIUM; TISSUE DISTRIBUTION; ANIMAL; CYTOLOGY; ENERGY METABOLISM; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ARTHRITIS; CYCLOOXYGENASE 2; EICOSANOIDS; ENERGY METABOLISM; FATTY ACIDS; HUMANS; INFLAMMATION MEDIATORS; ISOENZYMES; LIGANDS; MEMBRANE PROTEINS; MONOCYTES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTORS;

EID: 0036006943     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (125)

1. The nuclear receptor superfamily: The second decade
2. The peroxisome proliferator-activated receptor (PPARγ) as a regulator of monocyte/macrophage function
3. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions
4. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators
5. Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment
6. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
7. Peroxisome proliferator-activated receptors in the cardiovascular system
8. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene
9. A role for fatty acids and liver fatty acid binding protein in peroxisome proliferation?
10. Characterization of protein-DNA interactions within the peroxisome proliferator-responsive element of the rat hydratase-dehydrogenase gene
11. p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha
12. An adipogenic cofactor bound by the differentiation domain of PPARγ
13. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
14. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors
15. Association ol peroxisome proliferator-activated receptor and Hsp72
16. The orphan nuclear hormone receptor LXR alpha interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling
17. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor
18. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
19. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARγ) agonists. PPARγ co-association with transcription factor NFAT
20. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
21. The role of PPAR-γ in macrophage differentiation and cholesterol uptake
22. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development
23. Expression of the peroxisome proliferator-activated receptor gamma (PPARγv) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
24. Macrophages in human atheroma contain PPAR gamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro
25. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
26. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses
27. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells
28. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
29. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPARγ activators
30. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
31. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARγ activation modulates the effects of interleukin-1 beta on rat chondrocytes
32. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1 beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes
33. Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1
34. 15-Deoxy-delta(12,14)- PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
35. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation
36. A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: Characterization of peroxisome proliferator-activated receptor activators in plasma
37. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
38. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
39. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
40. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
41. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
42. Peroxisome proliferator-activated receptor agonists
43. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
44. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma
45. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
46. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
47. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
48. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ)
49. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice
50. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
51. Differentiation of ob 17 preadipocytes to adipocytes. Triggering effects of clofenapate and indomethacin
52. Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin
53. PPAR tissue distribution and interactions with other hormone-signaling pathways
54. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
55. Biologic agents for treating rheumatoid arthritis. Concepts and progress
56. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?
57. Anti-interleukin-1 therapy in rheumatic diseases
58. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis
59. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?
60. PPARγ agonists inhibit production of monocyte inflammatory cytokines
61. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
62. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo
63. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin-1
64. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
65. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
66. Etiopathogenesis of osteoarthritis
67. Metalloproteases and their modulation as treatment in osteoarthritis
68. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: Evidence for an inducible "neuronal- like" nitric oxide synthase
69. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
70. The NF-kappa B activation pathway: Its regulation and role in inflammation and cell survival
71. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation
72. Occurrence of 9-deoxy-delta 9,delta 12-13,14-dihydroprostaglandin D2 in human urine
73. Feedback control of cyclooxygenase-2 expression through PPAR
74. Tumor necrosis factor-alpha inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages. Synergistic action of cyclic AMP on cyclooxygenase-2 expression and prostaglandin E2 synthesis
75. Differences in the production of arachidonic acid metabolites between healthy and rheumatic synovial fibroblasts in vitro. A preliminary study
76. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs
77. Pathogenesis of bone erosions in rheumatoid arthritis
78. Troglitazone and related compounds: Therapeutic potential beyond diabetes
79. T-cell-dependent pathways in rheumatoid arthritis
80. Degradation of human articular cartilage by neutrophils in synovial fluid
81. How important are T cells in chronic rheumatoid synovitis?
82. Th1/Th2 cytokine balance in arthritis
83. Human interleukin-17: AT cell-derived proinflammatory cytokine produced by the rheumatoid synovium
84. Peroxisome proliferator-activated receptor gamma (PPAR-γ) activation in naive mouse T cells induces cell death
85. Isolation of the human peroxisome proliferator activated receptor gamma cDNA CDNA: Expression in hematopoietic cells and chromosomal mapping
86. 15-Deoxy-delta 12,1412,14-prostaglandin J2 inhibits the beta 2 integrin-dependent oxidative burst: Involvement of a mechanism distinct from peroxisome proliferator-activated receptor gamma ligation
87. Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications
88. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-deltal2, 14-prostaglandin J2
89. Chemokines - Chemotactic cytokines that mediate inflammation
90. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor
91. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model
92. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 I in cytokine-treated human vascular endothelial cells
93. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
94. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
95. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
96. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study
97. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates
98. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis: A double-blind placebo controlled study
99. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 I tumor necrosis factor by mononuclear cells
100. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids
101. Immunosuppressive effects of fish oil in normal human volunteers: Correlation with the in vitro effects of eicosapentaenoic acid on human lymphocytes
102. n-3 fatty acid supplements in rheumatoid arthritis
103. Cytokines, prostaglandins, and NSAIDs in cartilage integrity
104. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis
105. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases
106. Biological activities and mechanisms of action of PGJ2 and related compounds: An update
107. Inducible cyclooxygenase may have anti-inflammatory properties
108. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
109. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
110. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
111. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/ peroxisome proliferator-activated receptor gamma (PPARγ) heterodimer. A basis for new therapeutic strategies
112. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma
113. Cyclopentenone prostaglandins suppress activation of microglia: Down-regulation of inducible nitric-oxide synthase by 15-deoxy-deltal2,14-prostaglandin J2
114. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
115. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15- deoxy-delta(12,14)-prostaglandin J(2) in activated murine macrophages
116. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway
117. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
118. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
119. The PPARalpha-leukotriene B4 pathway to inflammation control
120. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb
121. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging
122. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
123. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia
124. Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643
125. Activation of nuclear factor-kappaB by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants N-acetylcysteine and vitamin E